Menu Search
Equities

New Ray Medicine International Holding Ltd

6108:HKG.HZ

New Ray Medicine International Holding Ltd

Actions
  • Price (HKD)0.046
  • Today's Change-0.003 / -6.12%
  • Shares traded640.00k
  • 1 Year change+2.22%
  • Beta--
Data delayed at least 15 minutes, as of Nov 15 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in HKDIncome statement in HKDView more

Year on year New Ray Medicine International Holding Ltd had revenues fall -44.13% from 89.77m to 50.15m, though the company grew net income from a loss of 77.95m to a smaller loss of 22.17m.
Gross margin29.02%
Net profit margin-35.98%
Operating margin-31.07%
Return on assets-2.52%
Return on equity-2.68%
Return on investment-2.65%
More ▼

Cash flow in HKDView more

In 2023, cash reserves at New Ray Medicine International Holding Ltd fell by 50.46m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 45.41m for operations while cash used for investing totalled 6.01m.
Cash flow per share-0.0028
Price/Cash flow per share--
Book value per share0.2803
Tangible book value per share0.2795
More ▼

Balance sheet in HKDView more

New Ray Medicine International Holding Ltd appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio17.97
Quick ratio16.98
Total debt/total equity0.0009
Total debt/total capital0.0009
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.